Michael Demurjian

Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that aims to disrupt the cancer cell's protein synthesis. The company was founded by Steve Hoffman and Michael Demurjian on November 22, 2011 and is headquartered in Bedminster, NJ.

Part of Syros Pharmaceuticals, Inc., Tyme, Inc. is a company that provides research and development services focused on developing drug candidates for the treatment of cancer. The company is based in Wilmington, DE. Steve Hoffman has been the CEO of the company since 2013. Tyme was acquired by Tyme Technologies, Inc., part of Syros Pharmaceuticals, Inc. from September 19, 2022 on March 05, 2015.

Mikronite Technologies Group, Inc. provides material surfacing technologies. The company was founded by Michael Demurjian and Steve Hoffman and is headquartered in Eatontown, NJ.

Aspargo Laboratories, Inc. is a clinical stage pharmaceutical company, which focuses on developing an oral spray formulation of sildenafil. Its products include Sildenafil Oral Spray, an oral liquid suspension of sildenafil citrate administered via a spray pump that dispenses 12.5 mg of sildenafil per push of the pump or via an individual single liquid unit dispensing 100 mg per unit. The company was founded in 2019 and is headquartered in Englewood Cliffs, NJ.